Purpose: One hundred eyes from 55 adult patients with myopia were retrospectively studied to determine the comparative safety, efficacy, and predictability of aberration smart ablation (ASA) and a new advanced ablation algorithm (Triple-A) using the MEL ® 80 excimer laser. Methods: Fifty myopic eyes with a manifest refraction spherical equivalent (MRSE) between -1.0 diopters (D) and -9.75 D were consecutively treated with photorefractive keratectomy ASA, and 50 myopic eyes with an MRSE between -1.38 D and -11.0 D with photorefractive keratectomy Triple-A. Uncorrected distance visual acuity, MRSE, the absolute value of the cylinder, corrected distance visual acuity, and postoperative complications at 1 month, 3 months, 6 months, and 12 months (1 year) were descriptively analyzed and compared at 1 year.
Introduction
In 1988, photorefractive keratectomy (PRK), a technique for laser refractive surgery, was introduced. 1 The correction of myopic refractive errors with the MEL ® 80 spot-scanning excimer laser (Carl Zeiss Meditec AG, Jena, Germany) with the aberration smart ablation (ASA) profile during PRK has been reported with good outcomes in terms of safety, efficacy, predictability, and the low incidence of vision-threatening complications. [2] [3] [4] The ASA profile is an aspheric optimized ablation profile. It has an aspheric profile portion that is independent of the correction. In some cases, the ASA profile used still has distinct imperfections, such as an underablation on the peripheral cornea. The use of ASA in higher myopic corrections can induce a positive spherical aberration, (Z 4 0 0). 5 Another detail of the ASA profile is that the use of this algorithm leads to a relatively higher ablation depth in low myopic corrections. This is because the asphericity has a constant amount over the total range of correction. In high myopic corrections, this amount is relatively low and leads to an induction of the higher order spherical aberration Z 4 0 . Dausch et al To achieve a minimal ablation depth during the correction of low myopia, an improved ablation profile should have a minimal asphericity in low corrections that increases as the amount of the myopic correction increases. Moreover, the improved ablation profile should include a more powerful energy correction function that minimizes the induction of a spherical aberration generally. The Triple-A advanced ablation algorithm is an ideal ablation profile comprising these properties and was developed by Carl Zeiss Meditec AG. As a part of the corneal topography guided treatment modality it was initially introduced commercially on the CRS-Master (Carl Zeiss Meditec AG) at the American Academy of Ophthalmology meeting in Los Angeles, (CA, USA) in 2005. The CRS-Master is a planning station for customized vision correction. It is available in many countries worldwide; however, it is currently not available in the US and Japan.
Even though laser algorithms have been established to optimally treat all types of refractive errors, in some patients, the postoperative vision deteriorates under mesopic and lighting conditions. 6, 7 The aim of the current study was to compare PRK in myopic patients using the MEL ® 80 excimer laser with the ASA or Triple-A ablation profile. Both ASA and Triple-A ablation profiles have been shown to be highly effective over a wide range of myopic corrections (-0.0 [diopters] D to -10.0 D). [2] [3] [4] 8 This retrospective study evaluated the safety, efficacy, and predictability of Triple-A (group B) and compared the same postoperative outcomes against patients triaged to receive standard ASA treatment (group A), both performed with the MEL ® 80 excimer laser.
Materials and methods study design
The study was conducted at Augenpraxisklinik Amberg, Marienstrasse 3, Amberg, Germany. At 1 year, the safety index, efficacy index, the postoperative MRSE, and the cylinder of both groups were compared. Also, the best corrected distance visual acuity (CDVA) under glare and under low contrast of both groups were compared. The purpose of the study is to compare the separate inferential test of mean and variances of the parameters at 1 year. Only primary treatments were analyzed. The follow-up rate was 100%. Outcome measures were calculated according to the standardized graphs as originally defined by Waring. 14 The logarithm of the minimum angle of resolution (logMAR) monocular UDVA, CDVA, and the manifest refraction were used to analyze the efficacy, safety, predictability, accuracy, stability, and the statistical calculation. Preoperative data, as well as 1-month, 3-months, 6-months, and 1-year postoperative data, were used for analysis ( 
exclusion criteria
Patients with corneal scarring, autoimmune disorders, severe dry eyes, blepharitis, or lagophthalmos were excluded from the study.
Preoperative, postoperative measurements
Preoperative and postoperative measurements included uncorrected distance visual acuity (UDVA) and best CDVA at 1 month, 3 months, 6 months, and 1 year. Pachymetry and refraction with and without cycloplegia were performed in all patients before surgery. Keratometer readings, autorefraction, and visual acuity (VA) under glare and low-contrast were performed in all eyes, at each visit, using the Humphrey Automatic Refractor 515 (Carl Zeiss Meditec, Jena, Germany). Furthermore, slit lamp examination, and topographic measurements were performed in all eyes, at each visit. Intraocular pressure was measured by Goldmann applanation tonometry preoperatively and after each follow-up month. The severity of postoperative subepithelial haze was graded, according to a classification system devised by the authors. 9, 10 surgical protocol
The optical zone varies between 5.5 mm and 6.5 mm, according to the scotopic pupil of the eyes ( 
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Full case analysis of PrKs in 100 eyes with 1-year follow-up 6.05±0.182 mm in the Triple-A group. Statistically, the mean of both groups turned out equal (P=0.34).
Because all of the measurements were performed at least under mesopic conditions and because the mean of the optical zones of both groups was equal, there was no consideration to do further analysis.
Before doing the surgical procedure, eyes were anesthetized with Novesine 0.4% eye drops (oxybuprocaine HCl 4 mg; OmniVision GmbH, Puchheim, Germany). Then, a lid-speculum was inserted. According to the desired treatment zone, the corneal surface was marked with an optical zone marker. Removal of the epithelium was done by using an Amoils brush (Innovative Excimer Solutions, Toronto, OT, Canada), according to the marked zone area. To test the correlation between age and 1-year UDVA, the Spearman rank correlation was used. The Spearman rank correlation was also used to test the correlation between age and 1-year SEQ.
The efficacy index and the safety index were performed with the following formulas. According to these, the ratio between UDVA postoperatively and CDVA preoperatively was made per eye, and the average of the ratio was calculated: 
Furthermore, the mean value of the differences between CDVA under glare and low contrast postoperatively and CDVA under glare and low contrast preoperatively were used for the analysis. 
Results
The study population consisted of 55 patients, 29 in the ASA treatment arm (group A), and 26 in the Triple-A treatment arm (group B). There were 100 eyes total; 50 in each arm. All surgeries were performed by one surgeon (DD). No eye required or underwent any retreatment.
The preoperative demographics are shown in The F-test and two-sided t-test were only used for the comparison of the sphere and MRSE preoperatively, because these variables turned out to be normally distributed for both groups (ASA and Triple-A).
All results of statistical calculation are listed in Table 9 .
Efficacy
The average UDVA at 1 year postoperatively was better than the CDVA preoperatively (efficacy index =1.03±0.15) for the Triple-A group patients. In the ASA group, the efficacy index was 0.95±0.3. The variance and mean of both groups were statistically different (P=0.011 and P=0.015). At 1 year postoperatively, 86% of the ASA group patients had a UDVA of 20/32 or better. Preoperatively, the CDVA of 20/32 or better was found in 96% of patients. In the Triple-A group, all patients (100%) had at least a UDVA of 20/32. Preoperatively, the CDVA of 20/32 or better was 98%. Sixty-eight percent (68%) of patients in the ASA group had a UDVA of 20/20 or better; whereas, 80% of the Triple-A group patients had a UDVA of 20/20 or better. Preoperatively, 86% of the ASA group patients had a CDVA of 20/20 or better; whereas, 82% of the Triple-A group patients had a CDVA of 20/20 or better ( Figure 1 ; Table 5 ).
safety
One year following surgery, the safety index of the ASA group was 1.06±0.24 compared to 1.05±0.15 in the Triple-A group. Statistically, there was no difference (P=0.69). The CDVA remained unchanged in fewer patients in the ASA group compared to the Triple-A group (56% versus 70%) after 1 year. One line of CDVA was lost in 20% of ASA patients compared to 8% of the Triple-A patients. One line of CDVA was gained in 20% of ASA patients compared to 18% of the Triple-A patients. One patient in the ASA group gained two lines of CDVA compared to two patients in the Triple-A group. One month postoperatively, the safety index (1.04±0.17) of the Triple-A group was higher than the safety index (0.99±0.18) of the ASA-group (Figure 2 ; Table 6 ). 
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Predictability/accuracy
Results for the entire cohort of 50 eyes each are presented in Figure 3 . The scatter plot shows the attempted versus achieved refraction at 1 year. The MRSE postoperatively is significantly better for the Triple-A group at 1 year (P0.0001). Also, 50% of the ASA and 86% of the Triple-A treated eyes had an MRSE between -0.13 D to +0.13 D after 1 year (Figure 4 ; Table 7 ). In the Triple-A group, no patient had any cylinder at 1 year postoperatively ( Figure 5 ; Table 8 ). The statistical analysis shows that the mean and variance were significantly different (P=0.0225; P=0.0232).
stability
The stability of the MRSE is presented in Figure 6 . The timeline depicts MRSE and one standard deviation re presented by the error bars preoperatively, and at 1 month, 3 months, 6 months, and 1 year after surgery. In the ASA group, three eyes had a regression of the MRSE 0.5 D between 6 months and 1 year, postoperatively. In the Triple-A group, no eye had a regression 0. 
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Full case analysis of PrKs in 100 eyes with 1-year follow-up Table 7 accuracy Mrse distribution postoperatively 0%  2%  2%  4%  8%  38%  40%  4%  2%  0%  0%   3 months 2%  0%  0%  8%  16%  38%  36%  0%  0%  0%  0%   6 months 2%  4%  2%  2%  10%  48%  32%  0%  0%  0%  0%   1 year  2%  4%  6%  6%  10%  50%  22%  0%  0%  0% 0%  0%  0%  0%  0%  58%  40%  2%  0%  0%  0%   3 months 0%  0%  0%  0%  4%  82%  12%  2%  0%  0%  0%   6 months 0%  0%  0%  2%  8%  86%  2%  2%  0%  0%  0%   1 year  0%  0%  0%  2%  8%  86%  4%  0%  0%  0%  0% Abbreviations: Mrse, manifest refraction spherical equivalent; asa, aberration smart ablation; Triple-a, advanced ablation algorithm. 18%  24%  16%  6%  4%  8%  14%  8%  0%  2%  0%  1 month 84%  10%  2%  2%  0%  2%  0%  0%  0%  0%  0%  3 months 94%  4%  0%  0%  2%  0%  0%  0%  0%  0%  0%  6 months 94%  4%  0%  2%  0%  0%  0%  0%  0%  0%  0%  1 year  92%  6%  0%  2%  0%  0%  0%  0%  0%  0% 
Spherical equivalent refraction (D)
A (ASA) Visual acuity under low contrast After 1 year, the mean value of the differences of the CDVA under low contrast for the ASA group was 0.03±0.20 log-MAR and for the Triple-A group, 0.06±0.16 logMAR. Statistically, there was no difference between both groups with respect to mean and variance (P=0.89; P=0.77).
Discussion
Excimer lasers -such as the MEL ® 80 -have revolutionized the field of laser eye surgery. They are used to reshape the cornea and correct refractive errors, such as myopia, hyperopia, and astigmatism. Ablation of the cornea with the MEL ® 80 excimer laser to treat myopia has been found to be safe and effective, achieving LASIK outcomes that are better than the US Food and Drug Administration guidelines for refractive procedures. 14, 15 Surface ablation to treat myopia induces spherical aberrations. [16] [17] [18] This is because the cornea is not completely spherical. Broad-beam ablation with lasers leads to an increase of spherical aberrations due to the asphericity of the cornea. Currently, the surgical focus is on treating myopic eyes with aspheric optimized ablation techniques.
Our study compared the outcome of ASA profile with the outcome of the Triple-A profile. Previous studies have shown that less spherical aberration is induced by modern ablation profiles than with conventional surface ablation techniques. 8, 19 Regarding refractive outcomes, the Triple-A group showed superiority. One year postoperatively, the mean MRSE (-0.02 D) was extraordinarily small, as well as the standard deviation (±0.15 D) of the same (Table 4) . Recent studies also showed a mean MRSE of -0.12 D ±0.35 D, 20 and -0.03 D ±0.15 D. 21 Also, 1 year after the procedure, nearly all patients (96%) in the Triple-A group had an uncorrected visual acuity of 20/25 or better. This was not the case in the ASA group. Differences in VA under glare and under low contrast were not statistically significant. The cylinder correction for the Triple-A treated patients was much more successful than for the ASA-treated patients. No eye in the Triple-A group had a cylinder postoperatively.
Conclusion
The present study showed the Triple-A profile to be as good as a standard ablation algorithm as ASA in terms of safety, predictability (slope), stability, and VA under glare and low contrast. Compared with ASA, the Triple-A showed superiority with respect to cylinder corrections, efficacy and predictability (scatter), and accuracy; therefore, it led to high patient satisfaction.
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